The halt prompted the company to predict it will now hit the bottom end of its full-year revenue range, a revision that surprised some analysts.
Medtechdive Share
The robot developer’s CEO, Benjamin Sexson, tells MedTech Dive why he believes the orthopedics market needs a fresh approach to joint reconstruction.
Medtechdive Share
Improvements in IV catheters can lead to better, more compassionate care, says Joseph Smith, BD’s chief scientific officer.
Medtechdive Share
New weight-loss drugs are eroding demand for surgical procedures that employ the company’s robotic systems.
Medtechdive Share
The company will fix or replace older devices still in use at hospitals as it ramps up to resume sales in its market-leading infusion business.
Medtechdive Share
The time it took for the FDA to reach 510(k) decisions decreased by 24 days, but the agency is still working through a pandemic-driven backlog of premarket approval applications.
Medtechdive Share
